Camurus
Develops and commercializes long-acting medicines for severe and chronic diseases.
CAMX | ST
Overview
Corporate Details
- ISIN(s):
- SE0007692850 (+2 more)
- LEI:
- 5493003S6Z6VI7WYFQ06
- Country:
- Sweden
- Address:
- Ideon Science Park, 223 70 Lund
- Website:
- https://www.camurus.com/
- Sector:
- Manufacturing
Description
Camurus is a science-led biopharmaceutical company that develops and commercializes innovative, long-acting medicines for severe and chronic diseases. The company specializes in advanced drug delivery systems designed to improve treatment outcomes, enhance patient quality of life, and provide value to society. Its therapeutic focus areas include opioid dependence, cancer and supportive care, endocrine conditions, rare diseases, and disorders of the central nervous system. Camurus maintains a diversified research and development pipeline to address significant unmet medical needs.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2019-02-06 07:00 | English | 2.3 MB | |||
| 2019-02-06 06:50 |
Camurus to progress commercialization of Buvidal and advance pipeline programs …
|
English | 151.5 KB | ||
| 2019-02-06 06:50 |
Camurus fortsätter kommersialisering av Buvidal och utveckling av läkemedelskan…
|
Swedish | 152.2 KB | ||
| 2019-01-11 08:00 |
Buvidal® launched as the first long-acting opioid dependence treatment in the EU
|
English | 165.8 KB | ||
| 2019-01-11 08:00 |
Buvidal® lanserad som första långtidsverkande behandlingen mot opioidberoende i…
|
Swedish | 181.1 KB | ||
| 2018-12-23 15:00 |
US FDA issues a tentative approval of Brixadi™ (buprenorphine) extended-release…
|
English | 206.3 KB | ||
| 2018-12-23 15:00 |
FDA utfärdar tentativt godkännande för Brixadi™ (CAM2038) för behandling av opi…
|
Swedish | 159.0 KB | ||
| 2018-12-04 10:04 | English | 34.6 KB | |||
| 2018-11-28 22:30 |
Buvidal® Weekly and Buvidal® Monthly (CAM2038) approved in Australia as the fir…
|
English | 1.3 MB | ||
| 2018-11-28 22:30 |
Buvidal® godkänd som första långtidsverkande behandling av opioidberoende i Aus…
|
Swedish | 727.0 KB | ||
| 2018-11-22 12:00 |
Camurus receives EU approval for weekly and monthly Buvidal® (CAM2038) for opio…
|
English | 85.6 KB | ||
| 2018-11-22 12:00 |
Camurus får EU-godkännande för Buvidal® (CAM2038) vecko- och månadsdepåer mot o…
|
Swedish | 86.1 KB | ||
| 2018-10-25 07:00 | Swedish | 2.3 MB | |||
| 2018-10-25 07:00 | English | 2.3 MB | |||
| 2018-10-16 07:00 |
Valberedning utsedd inför Camurus årsstämma 2019
|
Swedish | 60.7 KB |
Automate Your Workflow. Get a real-time feed of all Camurus filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Camurus
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Camurus via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-07-17 | Torsten Malmström | Other | Sell | 10,000 | 6,806,400.00 SEK |
| 2024-06-17 | Jon Uguzne Garay Alonso | Other | Other | 33,750 | N/A |
| 2024-05-14 | Torsten Malmström | Other | Sell | 1,495 | 844,675.00 SEK |
| 2024-05-10 | Annette Mattsson | Other | Sell | 1,000 | 550,000.00 SEK |
| 2023-12-15 | Annette Mattsson | Other | Other | 1,000 | 169,500.00 SEK |
| 2023-09-18 | Annette Mattsson | Other | Sell | 1,000 | 294,600.00 SEK |
| 2023-09-06 | Maria Lundqvist | Other | Other | 381 | N/A |
| 2023-08-23 | Maria Lundqvist | Other | Sell | 77 | 22,610.28 SEK |
| 2023-08-23 | Maria Lundqvist | Other | Sell | 58 | 17,032.86 SEK |
| 2023-08-23 | Maria Lundqvist | Other | Other | 77 | 13,051.50 SEK |
Peer Companies
